Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States.
Center for Cancer Research Protein Expression Laboratory, National Cancer Institute, Frederick, Maryland 21702, United States.
J Proteome Res. 2024 Oct 4;23(10):4715-4728. doi: 10.1021/acs.jproteome.4c00606. Epub 2024 Sep 5.
Proximity labeling (PL) has given researchers the tools to explore protein-protein interactions (PPIs) in living systems; however, most PL studies are performed on intracellular targets. We have adapted the original PL method to investigate PPIs within the extracellular compartment, which we term extracellular PL (ePL). To demonstrate the utility of this modified technique, we investigated the interactome of the matrisome protein TIMP2. TIMPs are a family of multifunctional proteins that were initially defined by their ability to inhibit metalloproteinases, the major mediators of extracellular matrix (ECM) turnover. TIMP2 exhibits broad expression and is often abundant in both normal and diseased tissues. Understanding the functional transformation of matrisome regulators, such as TIMP2, during disease progression is essential for the development of ECM-targeted therapeutics. Using dual orientation fusion proteins of TIMP2 with BioID2/TurboID, we describe the TIMP2 proximal interactome (MassIVE MSV000095637). We also illustrate how the TIMP2 interactome changes in the presence of different stimuli, in different cell types, in unique culture conditions (2D vs 3D), and with different reaction kinetics, demonstrating the power of this technique versus classical PPI methods. We propose that screening of matrisome targets in disease models using ePL will reveal new therapeutic targets for further comprehensive studies.
接近标记 (PL) 为研究人员提供了在活系统中研究蛋白质-蛋白质相互作用 (PPI) 的工具; 然而,大多数 PL 研究都是针对细胞内靶标进行的。我们已经对原始 PL 方法进行了改编,以研究细胞外隔室中的 PPI,我们将其称为细胞外 PL (ePL)。为了证明这种改进技术的实用性,我们研究了基质蛋白 TIMP2 的相互作用组。TIMP 是一类多功能蛋白,最初是根据其抑制金属蛋白酶的能力来定义的,金属蛋白酶是细胞外基质 (ECM) 周转的主要介质。TIMP2 广泛表达,在正常和患病组织中通常丰富。了解基质调节因子(如 TIMP2)在疾病进展过程中的功能转化对于开发针对 ECM 的治疗方法至关重要。我们使用 TIMP2 与 BioID2/TurboID 的双定向融合蛋白,描述了 TIMP2 的近端相互作用组(MassIVE MSV000095637)。我们还说明了在不同刺激、不同细胞类型、独特的培养条件(2D 与 3D)下以及不同反应动力学下,TIMP2 相互作用组如何变化,展示了与传统 PPI 方法相比,该技术的强大之处。我们建议在疾病模型中使用 ePL 筛选基质靶标,将为进一步的综合研究揭示新的治疗靶标。